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were collected for the health care services. Out-of-pocket (OOP) costs were the portion 
of individuals’ total payments for the health care services. To estimate the health care 
and OOP costs, a multivariable linear regression analysis was performed. Costs were 
adjusted for patient demographics and comorbidities. All costs were inﬂated using the 
medical component of the 2008 Consumer Price Index (CPI). RESULTS: There were 
873 individuals with PsO (mean age = 51 years; 52% female), and 160,617 individuals 
without PsO, (mean age = 48 years; 58% female). Annual per capita health care costs 
for individuals with PsO were higher than those for individuals without PsO ($4543 
vs. $3828; P = 0.0007). Annual per capita OOP costs for individuals with PsO were 
also higher than those of individuals without PsO ($1250 vs. $917; P < 0.0001). The 
total annual per capita direct medical costs was $5793 when combining health care 
and OOP costs for PsO. The US national annual estimates of health care, OOP, and 
total direct medical costs for PsO were $0.77 billion, $0.36 billion, and $1.1 billion, 
respectively. CONCLUSIONS: The direct medical costs associated with PsO are 
substantial not only to health care payers but to patients as well. The extent to which 
appropriate and early diagnosis and treatment of PsO reduce total health care costs 
for individuals with these diseases should be examined.
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OBJECTIVES: To quantify individual and national estimates of the indirect costs of 
inﬂammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), 
using national survey data. METHODS: This was a retrospective study using 1996–
2006 data from the Medical Expenditure Panel Survey (MEPS). Individuals self-
reported health conditions were mapped to the International Classiﬁcation of Diseases, 
9th Revision, Clinical Modiﬁcation (ICD-9-CM) diagnostic codes. Individuals with an 
ICD-9-CM diagnostic code of 555.x (CD) or 556.x (UC) were categorized as having 
IBD. A two-part model was speciﬁed to estimate the probability of time lost from 
work and the annual number of workdays missed due to illness, conditional on missing 
at least 1 workday. The annual missed workdays were combined with MEPS earnings 
information to estimate individual and national indirect costs. RESULTS: There were 
200 patients with IBD (mean age = 43.0 years; 54% Female), and 89,846 individuals 
without IBD (mean age = 40.8; 52% Female), included in the analysis. The study 
revealed 71.9% (144/200) of individuals with IBD missed work as compared with 
58.3% (52,110/89,846) of those without IBD (p = 0.0001). Among those individuals 
who missed work, individuals with IBD had a mean annual number of missed work-
days of 13.95 versus 9.83 missed workdays for individuals without IBD (p = 0.004). 
The per capita indirect costs associated with the incremental difference in annual lost 
workdays between those with and without IBD was $485. The estimated national 
indirect costs associated with IBD were $205 million per year. CONCLUSIONS: 
Compared to individuals without IBD, individuals with IBD have a higher probability 
of missing work and missing more workdays. The per capita and national annual 
indirect costs associated with IBD are substantial. The ability of appropriate and early 
diagnosis and treatment of IBD to reduce time lost from work and indirect costs for 
individuals with IBD should be examined.
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OBJECTIVES: To compare direct and absenteeism-related indirect expenditures 
among employees suffering from an AIID pre and post anti-TNF use. METHODS: A 
retrospective analysis was performed using the Thomson Reuters MarketScan® and 
the Health and Productivity Management databases (2000–2007). Study group con-
sisted of members with primary diagnosis for at least one of six AIIDs (Rheumatoid 
Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing 
Spondylosis) and at least one prescription for an anti-TNF (adalimumab, etanercept, 
or inﬂiximab) in the same calendar year. Direct expenditures included medical expen-
ditures (inpatient, outpatient, emergency department, and other medical services) and 
pharmacy expenditures. Indirect expenditures included expenditures related to absen-
teeism. Regression analysis was used to compare the mean number of annual absentee 
days, indirect expenditures associated with absences, direct expenditures (medical and 
pharmacy), and total expenditures during the 12 months prior versus the 12 months 
following initiation of anti-TNF treatment. RESULTS: The study group (n = 689) was 
39% female with 94% in a managed care plan and had a mean age of 44.3 years. 
Only 22% had more than one AIID condition. Following the use of anti-TNFs, 
absenteeism decreased by 15.4% with lower indirect expenditures ($1172 vs. $1000), 
lower medical expenditures ($7517 vs. $6434), and lower non anti-TNF pharmacy 
expenditures ($1934 vs. $1604). Direct expenditures were higher ($22,658 vs. $9450) 
due to the cost of anti-TNF treatment ($14,620). Consequently, total expenditures 
(direct and indirect) were also higher following anti-TNF use ($23,657 vs. $10,623). 
CONCLUSIONS: AIIDs are debilitating disorders that result in reduced productivity 
and time lost from work. Members with at least one AIID who received anti-TNF 
treatments, had lower absenteeism and indirect health care costs and higher direct 
costs. Appropriate management of these conditions with anti-TNF agents may provide 
greater indirect costs savings which could offset the direct costs.
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OBJECTIVES: To compare direct and absenteeism-related indirect expenditures 
among employees with inﬂammatory bowel disease (IBD) (Crohn’s Disease, Ulcerative 
Colitis) with employees who do not have IBD. METHODS: A retrospective analysis 
was performed using the Thomson Reuters MarketScan® and the Health and Produc-
tivity Management databases between 2000–2006. Propensity analysis adjusting for 
various demographic and clinical variables was used to create 1) control: no diagnosis 
of any IBD; and 2) IBD group: primary diagnosis of at least one IBD. Direct expen-
ditures included medical expenditures (inpatient, outpatient, emergency department, 
and other medical services) and pharmacy expenditures. Indirect expenditures 
included expenditures related to absenteeism. Regression analysis was used to compare 
the mean number of annual absentee days, indirect expenditures associated with 
absences, direct expenditures (medical and pharmacy), and total expenditures between 
the two groups. RESULTS: The 2201 employees in the IBD group were matched to 
8,788 employees in the control group (mean age 42.2 years; mean risk score was 3.43; 
40% female; with 94% in managed care). Compared to the control group, the IBD 
group had slightly higher rate of absenteeism (9.1 vs. 9.0 days, slightly higher indirect 
expenditures ($1170 vs. $1129), higher direct expenditures ($8870 vs. $7500) includ-
ing medical expenditures ($6860 vs. $6096), and non anti-TNF pharmacy expendi-
tures ($1609 vs. $1404). The total expenditures (direct and indirect) were also higher 
for the IBD group ($9950 vs. $8630) compared to the control group. CONCLU-
SIONS: IBD is a debilitating disease that results in reduced productivity and time lost 
from work. Employees with IBD have a higher total health care expenditure burden. 
Appropriate management of IBD can reduce costs for employers and payers. Further 
analyses are needed to determine the impact of various treatment(s) on lost productiv-
ity and direct and indirect expenditures.
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OBJECTIVES: To compare direct and absenteeism-related indirect expenditures pre- 
and post anti-TNF use among employees with inﬂammatory bowel disease (IBD). 
METHODS: A retrospective analysis was performed using the Thomson Reuters 
MarketScan® and the Health and Productivity Management databases between 
2000–2007. The study group consisted of individuals who had a primary diagnosis 
of at least one IBD and had at least one prescription for an anti-TNF agent (adalim-
umab, etanercept, or inﬂiximab) in the same calendar year. Direct expenditures 
included medical expenditures (inpatient, outpatient, emergency department, and 
other medical services) and pharmacy expenditures. Indirect expenditures included 
expenditures related to absenteeism. Regression analysis was used to compare the 
mean number of annual absence days and associated indirect expenditures, direct 
expenditures (medical and pharmacy), and total expenditures during the 12 months 
prior versus the 12 months following initiation of anti-TNF treatment. RESULTS: 
The study group had 87 members with a mean age of 41 years, 31% female, and 92% 
in a managed care plan. Following the use of anti-TNF agents, absenteeism was 39.8% 
lower (9.8 days vs.5.9 PMPY), and a similar decrease in indirect expenditures associ-
ated with absenteeism ($1,172 vs. $1,000) was observed. However, direct expendi-
tures were higher ($35,662 vs. $16,399) following the use of anti-TNF agents. This 
increase was primarily due to the cost of the anti-TNF agents themselves ($17,389), 
though annual medical expenditures were 13.2% higher ($15,810 vs. $13,968). Con-
sequently, total expenditures (direct and indirect) were also higher following anti-TNF 
use ($36,392 vs. $17,596). CONCLUSIONS: IBD results in reduced productivity and 
time lost from work. Members with at least one IBD who received anti-TNFs had 
lower absenteeism and lower indirect costs and higher direct costs. Employers and 
payers can develop appropriate management strategies like anti-TNF therapy to 
improve productivity and reduce indirect costs which may further offset total health 
care costs.
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OBJECTIVES: Develop a cost study and frequency of care for patients with chronic 
pain or neuropathic pain by occupational disease or consequences of occupational 
accidents in Colombia between 2002 and 2008, from the perspective of third-party 
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payer. METHODS: A retrospective study using double source of information both 
registration of authorized services and consumption of the insurer’s database as the 
histories of two institutions specialized pain care belonging to network service pro-
viders the same insurer, using a random sample of patients (n = 271) within a 
universe of 803 patients between 2002 and 2008. Using Bottom-up methodology is 
performed a micro-costing analysis grouping by frequency setting monthly consump-
tion and annual costs with measures of central tendency and dispersion, costs were 
estimated at constant prices of 2008. RESULTS: The average age of presentation 
of the diseases was 37 years, there were no signiﬁcant differences in gender distribu-
tion. (47.6% men and 52.4% women) The average total annual cost per patient 
was US$ 3322, the trend of the data series showed an increase of total costs in the 
period 2002–2006 and then a reduction in the period 2006–2008 with variable 
behavior depending on the category costs. The services represent a greater ﬁnancial 
burden are the outpatient medicines (35%) and osteosynthesis materials (30%). We 
estimated the annual expected frequency of use for a patient with these characteristics. 
It is possible that cost trends are explained by the incorporation of a pain manage-
ment program of the insurer with the use of new medicines that improve the clinical 
picture of patients. CONCLUSIONS: Chronic pain and neuropathic pain represent 
a signiﬁcant economic burden, is essential to identify the most cost effective interven-
tions in their management.
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OBJECTIVES: Obesity was associated with increasing morbidity and mortality of 
many chronic diseases, such as cardiovascular diseases, hypertension, diabetes melli-
tus, and stroke. Furthermore, the obese subjects had higher medical utilization with 
increasing BMI status, especially for the outpatient visits. The purpose of this study 
is to evaluate medical service utilization and medical expenditure associated with the 
obesity-related diseases in different weight status subjects in Taiwan. METHODS: A 
cross-sectional survey based on the National Health Interview Survey (NHIS) was 
conducted in 2001. Subjects greater than 20 years old who lived in Taiwan, correlated 
by National Health Insurance (NHI) during 2001–2004 were included and ﬁnally 
12,283 subjects were used for analyses. RESULTS: In general, male subjects were 
older, taller, heavier, larger BMI, higher medical utilization usage and expenditure 
than female. The higher BMI status, the higher prevalence of hypertension, type 2 
diabetes, cardiovascular diseases and gout. All obesity-related disorders had increasing 
trends with larger BMI (p < 0.001). Obese subjects (BMI ≥a 27 kg/m2) had the highest 
prevalence of hypertension (32.8%), following by Type 2 diabetes (25.6%). After 
adjusting for age, smoking, drinking and obesity-related disorders, the higher the BMI, 
the use of medical utilization in out-patient from 1.33 to 4.04 visit/year (p < 0.05) 
and in-hospital from 0.05 to 0.07 admission/year (p < 0.05). The average out-patient 
expenditure (all cost including physician-fee and drug cost) per year was NT$ 1201, 
1857, 3960 and 5118 dollars (exchange rate as 1USD = 32NTD) for underweight, 
normal, overweight and obesity subjects. CONCLUSIONS: In this study, the higher 
BMI status, the more medical utilization and higher out-patient medical expenditure 
was found. These results may help us to make decision on policy for resources alloca-
tion and strategies priority of obesity to resolve the major public health problem even 
in the developing country such as Taiwan.
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OVERLOAD ASSOCIATED WITH β-THALASSEMIA, SICKLE CELL 
DISEASE, AND MYELODYSPLASTIC SYNDROMES IN THE UNITED 
STATES (US)
Zhang B1, Donga PZ1, Corral M2, Miller JD1, Pashos CL1
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Novartis Pharmaceuticals 
Corporation, East Hanover, NJ, USA
OBJECTIVES: Patients with β-thalassemia, sickle cell disease (SCD), and myelodys-
plastic syndromes (MDS) require chronic blood transfusions, which lead to iron 
overload and substantial morbidity (e.g., cardiac failure, diabetes, hypothyroidism, 
hypogonadism) and mortality. To reduce the excess iron and its deleterious effects, 
available iron chelation therapy (ICT) in the US includes oral deferasirox or infusional 
deferoxamine (DFO). The aim of this literature review was to assess the economic 
burden of iron overload among US patients with β-thalassemia, SCD, and MDS. 
METHODS: We identiﬁed economic evaluations of iron overload in patients with 
β-thalassemia, SCD and MDS that either were published in MEDLINE-indexed, 
English-language journals since 1999, or appeared in professional society websites and 
scientiﬁc meeting abstracts. We summarized and critically compared costs (adjusted 
to 2009 USD) from this literature. RESULTS: The majority of studies assessed direct 
medical costs associated with iron overload among patients with β-thalassemia and 
SCD, where the association was reported as costs of ICT with DFO. Annual costs of 
patients with complications (notably cardiac disease, diabetes, etc.) varied from 
$72,000 to $103,000 per patient. Annual direct medical costs of patients undergoing 
ICT varied by disease—$47,000 and $74,000 per patient for β-thalassemia and SCD, 
respectively. Less information was available for MDS patients. ICT accounted for 
~33% of total medical costs, followed by costs for inpatient and outpatient care. Little 
information was available on costs incurred by untreated patients or those non-
compliant with their ICT. CONCLUSIONS: The economic burden of iron overload 
among transfusion dependent patients with β-thalassemia, SCD, and MDS in the US 
is substantial. The majority of information is on SCD and β-thalassemia, while the 
economic burden of iron overload in MDS is not clearly elucidated. More information 
is needed on the differential real-world impact of ICT choices on treatment adherence 
and on the economic burden overall.
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OBJECTIVES: To examine whether duloxetine initiators had different medication 
compliance or health care costs than pregabalin initiators among elderly patients with 
ﬁbromyalgia. METHODS: A large, US national claims database was analyzed to 
identify ﬁbromyalgia patients aged 65 and above with Medicare supplemental insur-
ance who initiated duloxetine or pregabalin in 2006. Initiation was deﬁned as no pill 
coverage in the previous 90 days, with the ﬁrst initiation date as the index date. All 
selected patients had 12-month continuous enrollment before and after the index date. 
Duloxetine initiators with diabetic peripheral neuropathic pain (DPNP) or depression, 
and pregabalin initiators with DPNP, post-herpetic neuralgia or epilepsy diagnosis in 
the 12-month pre-index period were excluded. Propensity scoring was applied to 
construct the duloxetine and pregabalin cohorts controlling for differences in demo-
graphics, pre-index clinical and economic characteristics, and pre-index treatment 
patterns. Medication compliance (i.e., medication possession ratio (MPR), proportion 
of patients with MPR ≥ 80%), and health care costs over the ﬁrst 12-month post-index 
period were examined between cohorts. RESULTS: Patients in the duloxetine (n = 
614) and pregabalin (n = 1188) cohorts had a mean age of 75 years. The most common 
comorbid conditions in both cohorts were cardiovascular disease (88.1% vs. 85.8%), 
neuropathic pain other than DPNP (72.5% vs. 72.2%), low back pain (71.6% vs. 
71.3%), and osteoarthritis (57.4% vs. 57.5%), while opioids (83.3% vs. 83.0%) were 
the most commonly prescribed medication over the 12 months pre-index period. 
Adjusting for demographics, pre-index clinical and economic characteristics, and prior 
medication history, duloxetine initiators had signiﬁcantly higher MPR (0.70 vs. 0.56, 
p < 0.05), higher proportion of patients with MPR ≥ 0.8 (44.8% vs. 29.0%, p < 0.05), 
and signiﬁcantly lower total health care costs ($26,323 vs. $27,112, p < 0.05) over 
the 12-month post-index period than pregabalin patients. CONCLUSIONS: Among 
elderly ﬁbromyalgia patients, duloxetine initiators had better medication compliance 
and lower direct health care costs than pregabalin initiators.
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OBJECTIVES: This study compared number of patient visits and out-of-pocket costs 
for multiple myeloma (MM) patients treated with bortezomib (BOR; Velcade®; IV 
administration), lenalidomide (LEN; Revlimid®; oral), thalidomide (THAL; Thalo-
mid®; oral), or other unspeciﬁed chemotherapies/radiation therapy. METHODS: 
Patients aged > = 18 yrs, diagnosed with MM between January 1, 2005 and September 
30, 2007, and treated with BOR, LEN, THAL, or other unspeciﬁed chemotherapies/
radiation therapy were identiﬁed using claims data from a large US commercial health 
plan (~14 million members). Treatment episodes (each course of therapy) were identi-
ﬁed from patient records. Health-care utilization (number of ambulatory patient visits) 
and inﬂation-adjusted patient out-of-pocket costs, including co-pays and deductibles, 
were examined for 1 yr from the beginning of each treatment episode. Multivariate 
regression analyses were performed to control for patient characteristics, comorbidi-
ties, and line of treatment. RESULTS: A total of 2642 treatment episodes for 1900 
patients were identiﬁed. Most episodes were “other chemotherapy/radiation therapy” 
(n = 1759), followed by THAL (n = 549), BOR (n = 244) and LEN (n = 90). There 
were no between-group differences in inpatient or emergency room visits. Patients 
treated with BOR appeared to have more ambulatory visits compared with patients 
treated with LEN (77 versus 61; p < 0.05); however, this difference was not signiﬁcant 
after multivariate analysis (66 versus 57; p > 0.05). The total adjusted patient out-of-
pocket costs were signiﬁcantly less for patients treated with BOR ($3504) than for 
those treated with THAL ($4443, p < 0.05) or LEN ($4766, p < 0.05). These differ-
ences were greatest for Medicare patients, with the adjusted patient costs of THAL 
($8,824) and LEN ($12,568) respectively, nearly 2 and 3 times greater than the 
adjusted costs of BOR ($4,395). CONCLUSIONS: There was no signiﬁcant advantage 
in terms of fewer patient visits with the oral drugs (THAL, LEN) over BOR. Direct 
out-of-pocket costs were signiﬁcantly higher for patients treated with THAL and LEN 
compared with BOR, especially for Medicare patients.
